Citius Oncology, Inc. (“Citius Oncology”) the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), a late-stage biopharmaceutical company advancing first-in-class critical care therapies, announced the deployment of a cutting-edge AI-driven platform to empower its commercial operations ahead of the anticipated launch of LYMPHIR™, an innovative treatment for cutaneous T-cell lymphoma (CTCL). This advanced system is designed to provide the commercial team with sophisticated data analytics and actionable insights, enabling smarter decision-making, improved targeting, and more efficient engagement with healthcare professionals.
The proprietary platform applies company-specific parameters to detect key patterns in diagnosis and treatment behaviors, allowing Citius Oncology’s team to swiftly identify prescribers whose patients could benefit from LYMPHIR. The system’s capacity to identify possible candidates for LYMPHIR is improved by its integrated machine learning capabilities, which also help the commercial team provide timely, relevant interventions that can enhance patient outcomes.
Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma, emphasized the transformative potential of the platform, stating, “This technology amplifies the expertise and effectiveness of our seasoned commercial and marketing teams. It equips them with a powerful tool to bridge clinical need, scientific innovation, and patient access in a more intelligent and scalable manner.”
The platform, which was designed as a continuously learning model, integrates marketing analytics with actual U.S. claims data to stay up to date with new treatment techniques and utilization trends. This dynamic approach ensures that the system delivers predictive insights, enabling customized content delivery and seamless customer engagement across both digital and in-person channels.
Through the integration of advanced analytics, machine learning, and an experienced commercial infrastructure, Citius Oncology aims to accelerate provider education, enhance decision-making, and ultimately expand access to critical treatment options for individuals battling CTCL. This initiative reflects the company’s commitment to leveraging innovation to optimize commercial efficiency and improve patient care in oncology.
